LyGenesis and Imagine Pharma to jointly develop cell therapies for Patients with Type 1 diabetes
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
The Award acknowledges Emcure's contribution in the field of HIV/AIDS to improve the quality of life of people living with HIV/AIDS.
The disease is caused by a mutation in the gene encoding HMG CoA reductase, inhibiting the enzyme’s activity.
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations
Department of Biotechnology is going to play an important part in the integrated holistic healthcare approach against elimination of Tuberculosis
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
This initiative encapsulates the essence of OPPI’s commitment towards enabling a healthier India
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
Subscribe To Our Newsletter & Stay Updated